etofibrate has been researched along with Hyperlipoproteinemia Type II in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (83.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goebel, KM; Hausmann, L; Kaffarnik, H; Schneider, J; Schubotz, R; Zöfel, P | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Altomonte, L; De Cunto, F; Greco, AV; Mingrone, G; Negrini, A | 1 |
| Udelhoven, P | 1 |
| Altomonte, L; Ghirlanda, G; Greco, AV; Manna, R; Mingrone, G; Pala, MA; Rebuzzi, A | 1 |
| Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W | 1 |
| Mertz, DP | 1 |
| Freyberger, H; Schatz, H; Schifferdecker, E | 1 |
| Banyai, M; Koller, E; Li, S; Pidlich, J; Pirker, W; Rauscha, F; Sinzinger, H; Virgolini, I; Yang, Q | 1 |
| Gustafson, A | 1 |
| Loewer, H; Mertz, DP; Suermann, I | 1 |
| Palmer, RH | 1 |
1 review(s) available for etofibrate and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
3 trial(s) available for etofibrate and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged | 1981 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
9 other study(ies) available for etofibrate and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransferase; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Long-Term Care; Male; Middle Aged; Triglycerides; Uric Acid | 1980 |
[Lipid lowering improved? Therapeutic progress by using biological mechanisms].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II | 1982 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides | 1980 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged | 1980 |
[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Topics: Adult; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fundus Oculi; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pilot Projects | 1994 |
Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Blood Platelets; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; In Vitro Techniques; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Stimulation, Chemical | 1993 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Liver Function Tests; Male; Middle Aged; Nicotinic Acids; Time Factors | 1979 |
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged | 1979 |